Cell-Based Assay Market Report with Forecast 2025 to 2034
Share With :
Global Cell-Based Assay Market Size is valued at USD 17.79 billion in 2023 and is predicted to reach USD 32.28 billion by the year 2031 at a 7.81% CAGR during the forecast period for 2024 to 2031.
Cell-Based Assay Market Size, Share & Trends Analysis Report By Product (Consumables, Instruments & Software, And Services), Application (Drug Screening, Basic Research, Predictive Toxicology), Technology (Flow Cytometry, Automated Handling, High Throughput Screening, High Content Screening), And End-User And Segment Forecasts, 2024 to 2031
Due to factors such as the rising need for drug discovery, the increased requirement for biotechnology research, and the increasing prevalence of infectious diseases, cancer, autoimmune diseases, and genetic disorders, the market is expected to experience rapid expansion.
In the drug discovery process, cell-based assays are frequently used to validate potential drug candidates, and assays are also used for toxicity studies, cellular signaling, and lead profiling. For instance, Cell Biologics' Annexin V-Cy3 apoptosis detection kit helps with the fluorescence method of detecting apoptosis.
Major clinical trials, medication discovery processes, and research activities were all interrupted by the COVID-19 pandemic. To catch up on the backlog of research, numerous researchers all around the world adopted efficient and less time-consuming study approaches.
Additionally, many cell-based assays have been developed to identify COVID-19 infection. The FDA has approved a number of tests for use in emergency situations everywhere. For instance, in May 2021, the U.S. FDA approved the T-Detect COVID-19 regular T-cell test (by Adaptive Biotechnologies) for emergency use. It is an NGS-based assay that helps to identify T-cells that recognize SARS-CoV-2 antigens for verification of recent infections.
The Cell-Based Assay market is categorized on the basis of product, application, technology, and end-user. Based on product, the market is segmented as consumables, instruments & software, and services. The application segment includes drug screening, basic research, predictive toxicology, and others. By technology, the market is segmented into flow cytometry, automated handling, high throughput screening, high content screening, and other technologies. The end-user segment includes pharmaceutical & biopharmaceutical companies, CROs, Academic research, and others.
The global industry was led by the drug discovery application category, which also contributed the largest percentage of total revenue. This expansion is attributed to the rising global demand for novel therapeutic drugs to treat a variety of diseases. A surge in therapeutic drug discovery research projects and increased market competitiveness for FDA clearances are driving the expansion of the drug discovery market segment.
The end-user category of pharmaceutical and biopharmaceutical firms controlled the global market. Cell-based assays are useful in the pharmaceutical business for determining how environmental stimuli or pharmacological substances affect cellular activity in general. Cell-based drug screening assays have also been frequently used in drug development research to select promising lead molecule candidates from hundreds of chemical compound libraries. Such extensive uses of cell-based assays in the pharmaceutical sector fuel segment expansion.
The global industry was dominated by the North American continent. It is projected that the region will continue to grow steadily, keeping its top position during the forecast period. The significant research conducted in several research institutes, financed jointly by academic research institutes and pharmaceutical behemoths around the globe, is primarily responsible for the market expansion in the North American region. For instance, in April 2022, Labcorp and Xcell Biosciences, Inc., agreed to work together to promote vital laboratory research aimed at enhancing the safety and efficacy of Cell & Gene Therapies (CGTs) to facilitate the successful launch of novel CGTs into the market.
| Report Attribute | Specifications |
| Market size value in 2023 | USD 17.79 Bn |
| Revenue forecast in 2031 | USD 32.28 Bn |
| Growth rate CAGR | CAGR of 7.81% from 2024 to 2031 |
| Quantitative units | Representation of revenue in US$ Billion, and CAGR from 2024 to 2031 |
| Historic Year | 2019 to 2023 |
| Forecast Year | 2024 to 2031 |
| Report coverage | The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends |
| Segments covered | Product, Application, Technology, And End-User |
| Regional scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
| Competitive Landscape | Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Danaher Corporation, Merck KGaA, Thermo Fisher Scientific, Inc., Corning Incorporated, Lonza Group AG, Agilent Technologies, Inc., Promega Corporation, PerkinElmer, Inc., Eurofins DiscoverX Products, Cell Signaling Technology, Inc., Charles River Laboratories International, Inc., and Laboratory Corporation of America Holdings. |
| Customization scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and available payment methods | Explore pricing alternatives that are customized to your particular study requirements. |
Cell-Based Assay Market By Product-
Cell-Based Assay Market By Application-
Cell-Based Assay Market By Technology-
Cell-Based Assay Market By End User-
Cell-Based Assay Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.